The Claim
Semaglutide increases neutrophil CD88 expression in obese adults with type 2 diabetes, where CD88 is a receptor associated with complement activation and inflammation, indicating an immunomodulatory effect distinct from simple anti-inflammatory action.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults with type 2 diabetes, semaglutide increases the presence of CD88 receptors on neutrophils, which are involved in complement activation and inflammation, suggesting a broader influence on immune regulation beyond reducing inflammation.
See the scientific wording
Semaglutide increases neutrophil CD88 expression in obese adults with type 2 diabetes, a receptor linked to complement activation and inflammation, which may reflect a complex immunomodulatory effect rather than simple anti-inflammatory action.
Semaglutide activates a receptor on fat cells and immune cells, which reduces a harmful fat signal that makes immune cells stick to blood vessels. At the same time, it increases a different receptor on immune cells that grabs a inflammatory molecule, removing it from the bloodstream and calming chronic inflammation in blood vessels.
What the research says
1 studyThe study found that a diabetes weight-loss drug called semaglutide made a specific immune cell signal (CD88) go up by 81% in obese diabetic patients, which means it’s changing how immune cells behave in a complex way — not just making everything calmer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.